Canada Approves Apotex's Bid to Sell Generic Version of Wegovy
By Paul Vieira
OTTAWA--Canadian regulators approved Apotex's bid to manufacture a generic version of the weight-loss drug Wegovy.
Canada's health department, which is in charge of drug approvals, said Monday it authorized Apotex's bid following a review of evidence from the company that meets the regulator's criteria for generic drugs. Wegovy is produced by Danish drug maker Novo Nordisk.
In April, Canada became the first Group of Seven economy to approve a generic version of semaglutide. At that time, Canada authorized a generic version of Ozempic developed by Dr. Reddy's Laboratories.
Canada said the semaglutide injection it approved is to be used once a week for patients 12 years and over as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management.
Canada's health department said many generic medication are anywhere from 45% to 90% cheaper than the brand-name versions.
Write to Paul Vieira at paul.vieira@wsj.com
(END) Dow Jones Newswires
June 29, 2026 17:49 ET (21:49 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
United States